ReviewCancer pathogenesis and therapy2023
Biomaterial-based
Review in Cancer pathogenesis and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Flash Assembloids: A Rapid Biofabrication of a Platform for Modeling Early Glioblastoma Invasion at the Glioblastoma-Brain Organoid Interfaces.Advanced healthcare materials · 2026Article
- Forming a Precise and Reproducible Hypoxic Tumor Microenvironment in Glioblastoma by High Cell Density Bioprinting.Advanced healthcare materials · 2026Article
- Engineering macrophages for cancer immunotherapy: emerging insights and therapeutic potential.npj biomedical innovations · 2026Review
- Primary glioma cell culture: from monolayer to organoids.Protoplasma · 2026Review
- GlioblastomaACS biomaterials science & engineering · 2026Article
- A mechanobiology-driven cell-derived ECM bioink for engineering 3D glioblastoma tumor microenvironment models.Theranostics · 2026Article
- 3D Brain Vascular Niche Model Captures Glioblastoma Infiltration, Dormancy, and Gene Signatures.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Evolution of Preclinical Models for Glioblastoma Modelling and Drug Screening.Current oncology reports · 2025Review
- Recent advances in 3D printing applications for CNS tumours.European journal of medical research · 2025Review
- Biomimetic Nanoparticle Based Targeted mRNA Vaccine Delivery as a Novel Therapy for Glioblastoma Multiforme.AAPS PharmSciTech · 2025Review
- Patient-Derived Glioblastoma Explants Empower Rapid and Personalized Drug Assessment: Harnessing the Potential of 3D Perfusion Bioreactors in Glioblastoma Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Emerging biomimetic biopolymer-based composites: advancing accessible and sustainable neural disease models and therapeutics.Frontiers in bioengineering and biotechnology · 2025Review
- Advancing Alzheimer's Disease Modelling by Developing a Refined Biomimetic Brain Microenvironment for Facilitating High-Throughput Screening of Pharmacological Treatment Strategies.International journal of molecular sciences · 2024Review
- Advancement in Cancer Vasculogenesis Modeling through 3D Bioprinting Technology.Biomimetics (Basel, Switzerland) · 2024Review
- Complex in vitro models: do not complicate it.In vitro models · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset brain cancers, such as glioblastomas, are particularly lethal. People with glioblastoma multiforme (GBM) do not anticipate living for more than 15 months if there is no cure. The results of conventional treatments over the past 20 years have been underwhelming. Tumor aggressiveness, location, and lack of systemic therapies that can penetrate the blood-brain barrier are all contributing factors. For GBM treatments that appear promising in preclinical studies, there is a considerable rate of failure in phase I and II clinical trials. Unfortunately, access becomes impossible due to the intricate architecture of tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.